Indaptus Therapeutics is trading 5.6% down at $1.36 as traders continue to lock in gains following the stock's recent sharp rebound.
- The decline follows a 13.5% drop on July 30, 2026, as the stock faces extended short-term selling pressure after a multi-day rally.
- With no fresh company-specific announcements, the move appears to be a continuation of profit-taking amid a generally weak backdrop for the biotech sector.